In a research study led by Yuksel Agca, associate professor of veterinary pathology and a researcher in the Comparative Medicine Program in the MU College of Veterinary Medicine, it was found that two proteins namely APP and PS1, were the key factors linked to Alzheimer’s disorder, by carrying out the research work in rat model. If the accumulation of amyloid-β could be manipulated, it could lead to a decrease in the onset of Alzheimer Disease.
EIP Pharma raised $20.5 million series B funding to support Neflamapimod, the phase 2b program of its Alzheimer treatment. The funding is also to build the team and to support other research studies related to central nervous system disorders.
IDx, a privately held AI diagnostics company, announced today that it has filed its De Novo submission to the FDA for IDx-DR, an AI-based system for the autonomous detection of diabetic retinopathy — a leading cause of blindness. The FDA has granted IDx-DR with a “Breakthrough Device” designation, which means the submission will receive expedited review.
Health technology and clinical wearables are hot topics in the healthcare and pharmaceutical industries. They are creating waves of excitement and talking points for debate, while also topping many of the healthcare trends of this year.
As Pfizer clears house of its unwanted neuro assets, Biogen has become a buyer for one, namely a phase 2-ready schizophrenia drug.
HAIFA, Israel and MIAMI, Florida – INSIGHTEC®, a commercial-stage medical technology company revolutionizing surgery with incisionless MRI-guided focused ultrasound (MRgFUS) announced today the closing of a $150 million Series E private equity investment round. Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, focused on finding and funding innovative and emerging companies, led the round with a $100 million investment.
Although it isn’t talked about often, older adults in the United States are turning to drugs and alcohol at an alarming rate. Studies have found that a large population of older Americans are suffering from substance use disorders, and the number is only expected to rise. According to research, the number of Americans aged 50 and older struggling with addiction is expected to nearly double in the coming years, going from 2.8 million to 5.7 million by 2020.
Stem cells have the unique capability to transform into any sort of specialized cell needed in the body, making them especially promising for medicine that replaces nonfunctional or dead cells.
Pfizer has signed on to fund the launch of a hunt for a slate of small molecules that can degrade proteins, a key therapeutic pathway that’s been playing a role in prostate cancer and other areas.
Johnson & Johnson (J&J) has signed 15 new partnerships to explore, develop and advance new medical devices, therapeutics and consumer health solutions.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.